Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eco-friendly reduced graphene oxide@potash alum-based composite membranes for efficient separation of dyes and selective removal of contaminants from wastewater.

RSC advances·2026
Same author

Nebulised heparin as a treatment for lung diseases: formulation challenges and pulmonary drug delivery strategies.

Lung·2026
Same author

Salubrious effects of proanthocyanidins on behavioral phenotypes and DNA repair deficiency in the BTBR mouse model of autism.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2026
Same author

Highly efficient TiO<sub>2</sub>-functionalized nylon-6 nanofibrous membranes for rapid adsorptive removal of atrazine from water.

RSC advances·2026
Same author

S3I-201, a STAT3 Inhibitor, Inhibits Proinflammatory Mediator Signalling in CD19 and CD45R/B220 Cells in a Mouse Model of Multiple Sclerosis.

Cellular and molecular neurobiology·2026
Same author

IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities.

Lung·2026

Related Experiment Video

Updated: Jun 21, 2026

In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

Adenosine receptors and asthma.

Constance N Wilson1, Ahmed Nadeem, Domenico Spina

  • 1Endacea, Inc., Research Triangle Park, NC 27709-2076, USA. cwilson@endacea.nctda.org

Handbook of Experimental Pharmacology
|July 30, 2009
PubMed
Summary

Adenosine and its receptor subtypes play key roles in asthma pathophysiology, influencing airway obstruction and inflammation. Targeting these adenosine receptors (ARs) offers potential for developing novel asthma treatments.

More Related Videos

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice
07:55

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice

Published on: May 5, 2011

Related Experiment Videos

Last Updated: Jun 21, 2026

In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice
07:55

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice

Published on: May 5, 2011

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Asthma pathophysiology involves complex processes with numerous potential therapeutic targets.
  • Adenosine, an endogenous substance, is implicated in asthma due to its effects on respiratory mechanics and pathology.
  • Adenosine is released during hypoxia, stress, allergic stimulation, and exercise, and acts on adenosine receptors (ARs).

Purpose of the Study:

  • To elucidate the roles of adenosine and adenosine receptor (AR) subtypes in asthma.
  • To explore the potential of targeting AR subtypes for novel asthma therapeutics.

Main Methods:

  • Review of preclinical in vitro and in vivo studies on AR subtypes in asthma models.
  • Analysis of the roles of adenosine and AR subtypes in airway obstruction, inflammation, hyperresponsiveness, and remodeling.
  • Evaluation of clinical studies involving AR agonists and antagonists for asthma treatment.

Main Results:

  • Adenosine receptor (AR) activation influences lung resident and inflammatory cell function.
  • Preclinical studies demonstrate beneficial impacts of modulating ARs in asthma models.
  • Development of AR agonists and antagonists has progressed to clinical trials.

Conclusions:

  • Adenosine and its receptor subtypes are significantly involved in characteristic asthma features.
  • Targeting specific adenosine receptor (AR) subtypes presents a promising strategy for novel asthma drug development.